Biodexa Pharmaceuticals (BDRX) Intangibles (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Intangibles of $7.5 million for Q4 2025, little changed sequentially from $7.5 million in Q2 2025, and up 3.62% YoY from $7.2 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Intangibles (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Intangibles for 13 years, with the latest figure at $7.5 million in Q4 2025.
- Quarterly Intangibles rose 3.62% year-over-year to $7.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.5 million (up 3.62% YoY) and the FY2025 annual result came in at $7.4 million, up 2.71% from the prior year.
- Intangibles was little changed at $7.5 million in Q4 2025 per BDRX's latest filing, from $7.5 million in the prior quarter.
- Over five years, Intangibles peaked at $21.1 million in Q4 2021 and troughed at $6256.8 in Q2 2023.
- A 5-year average of $9.1 million and a median of $7.5 million in 2025 frame the typical range for Intangibles.
- The sharpest annual moves came in 2023 and 2024: Intangibles sank 80.28% in 2023, then surged 121102.58% in 2024.
- Over 5 years, Intangibles stood at $21.1 million in 2021, then declined by 12.38% to $18.5 million in 2022, then tumbled by 80.28% to $3.7 million in 2023, then soared by 98.53% to $7.2 million in 2024, then gained by 3.62% to $7.5 million in 2025.
- According to Business Quant data, Intangibles over the past three periods registered $7.5 million, $7.5 million, and $7.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.03 Bn | 131.18 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 57.93 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.95 Bn | 36.86 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.00 Bn | 9.60 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | - |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - | 3.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.51 Mn |
| Jun 30, 2025 | 7.53 Mn |
| Dec 31, 2024 | 7.25 Mn |
| Jun 30, 2024 | 7.58 Mn |
| Dec 31, 2023 | 3.65 Mn |
| Jun 30, 2023 | 6,256.82 |
| Dec 31, 2022 | 18.51 Mn |
| Dec 31, 2021 | 21.12 Mn |
| Dec 31, 2020 | 20.69 Mn |
| Jun 30, 2020 | 966,039.17 |
| Dec 31, 2019 | 20.19 Mn |
| Jun 30, 2019 | 15.92 Mn |
| Dec 31, 2018 | 20.20 Mn |
| Jun 30, 2018 | 16.87 Mn |
| Dec 31, 2017 | 62.01 Mn |
| Jun 30, 2017 | 38.83 Mn |
| Dec 31, 2016 | 34.37 Mn |
| Jun 30, 2016 | 61.05 Mn |
| Dec 31, 2015 | 65.85 Mn |
| Dec 31, 2014 | 20.75 Mn |